Enterosorbent and method of its obtaining
SUBSTANCE: method includes milling glauconite with the content of rock from 20 to 95%, selection of a fraction of 1.0-10 mcm, preparation of a 40-80% suspension of glauconite in water. The obtained suspension is processed by ultrasound with a frequency of 15-25 kHz for 2-5 minutes. As a result obtained is a glauconite-based enterosorbent, which represents a 40-80% suspension of the glauconite 1.0-10 mcm fraction in water.
EFFECT: obtaining the glauconite-based enetrosorbent, which has the increased sorption ability in the form of a stable water suspension of glauconite.
2 cl, 2 tbl, 2 ex
The invention relates to biotechnology, namely to enterosorbents and technologies of their production, and is intended for use in health care for the normalization of the gastrointestinal tract and other body systems as well as related sectors of the economy (veterinary medicine, chemistry, cosmetics, pharmacy and food industry).
Chelators - products used for binding of metabolites, toxins and other substances in the digestive tract. They are usually, in solving optimization problems of nutrition of humans and animals, and also to reduce intake of environmentally harmful substances (including radionuclides, pesticides, heavy metals), the prevention and treatment of several diseases such as dysentery, viral hepatitis, drug and food allergies, asthma, diabetes, disorders of lipid metabolism.
As enterosorbents currently widely used various minerals, such as zeolites, bentonites, activated carbon, microcrystalline cellulose, zeolites, lignins and their derivatives.
The most well known use of enterosorbent activated carbon (Activated charcoal) (Reference VIDAL. Drugs in Russia. - M.: OVPEE - Astra Pharm Service, 2000 - P. E-8), widely used in hee�tiles, food, pharmaceutical industries and in medicine. However, it has relatively low sorption activity and low selectivity of the sorption of the action of such substances as cholesterol, bilirubin, urea, uric acid, are generally removed from the body by the excretory organs. In its application, possible constipation, diarrhea; and if long - term use, the vitamin deficiencies, malabsorption from the gastrointestinal tract nutrients. Activated charcoal is contraindicated in ulcerative lesions of the gastrointestinal tract, with gastric bleeding.
Known drug (RU 2124358, 1999) for the treatment of gastrointestinal diseases with aluminium phosphate as busy, but it only has effect on the reduction of acidity and is ineffective for removal from the body of toxic substances. Also known drug (BG around 61,500, 1997), which as enterosorbent use a mixture of aluminum hydroxide and magnesium in combination with lysozyme. It possesses bactericidal properties due to the presence of lysozyme, however, cannot absorb and excrete harmful toxic substances, and normalize the functions of the gastrointestinal tract.
It is known to use as chelators of shungite (EN 2423984, 2011) with the content of silicon dioxide �t 20 to 50 wt.%, while the average median particle size of the enterosorbent amounts to 15.0·10-6m zeolite-based opal-cristobalite breed (EN 2319488, 2008). The effective sorbents for use in combined radiation-thermal lesions of humans and animals, to relieve alcohol and drug intoxication, as an antibacterial agent as a means for the prevention and treatment of gastrointestinal diseases of agricultural animals and birds, but their efficiency is not high enough.
One of the promising chelators is glauconite. The name earth comes from the Greek "glaukos" bluish - green. Glauconite clay mineral of variable composition with a high content of ferrous and ferric iron, calcium, magnesium, potassium, phosphorus, which typically contains more than fifty trace elements, among which copper, silver, Nickel, cobalt, manganese, zinc, molybdenum, arsenic, chromium, tin, beryllium, cadmium and other (http:www.saratov-bi.ru/news/2013-04-16-000000). Fluctuations in composition are associated with isomorphic substitutions. By decision of the International nomenclature Committee of the glauconite should be called glandular dioctahedral mica. The content of the main components is normally in the range, %: Si2- 47-50,5; Al2O3- 5-10; Fe2O3- 15-22; FeO - 2-4; MgO - 3-4; aO - 0-0,8; Na2O - 0-0,5; K2O - 6-8; H2O - 7-9 (EN 2291702, 2007).
All trace elements are easily recoverable in the form of exchangeable cations that are replaced are in abundance in the environment. This property was attributed to the high sorption properties of glauconite in relation to toxins, petroleum products, heavy metals, radionuclides.
It is known the use of glauconite as a reactant in the processing of beverages for the purpose of clarification (EN 94021998, 1996), in foundry molding mixtures as substances intended to increase the suppleness of the mixture, with the aim of improving the quality of foundry cores and molds /SU 1388184, 1988); to reduce the hardness of the water, fertilizing the soil, the manufacture of paints (SES, Moscow, "Soviet encyclopedia", 1990, p. 313). In crop production it is used for reduction of pesticide residues in plants, improve seed germination, increase of bio-mass plants, as compound fertilizers are gradual steps for many crops (rice, millet, wheat, potatoes, corn, tomatoes and other), for the increase of green mass of annual grasses to improve water-physical status of the soil, to enhance the activity of soil microflora, increasing the germination and yield of legumes, root crops, tomatoes, cucumbers (Atlas unconventional agrochemical mi�of mineral raw materials of the USSR Ministry of Geology of the USSR; The Union reports. nauch.-issled. Institute of Geology and non-metallic minerals; Comp. P. O. Alamitos, A. I. Burov, I. S. Gusiev, etc.: edited by W. G. Destinova, A. S. Filko, V. F. Semenov. - M.: Nedra, 1989, 64 p., O. E. Akin, A. I. Kovalchuk Experimental research work on the use of opal-cristobalite breeds for growing plants / Report. NGO "Sredneuralskaya" (Uralniiskhoz) IgG RAS, Ekaterinburg, 1998). Studies conducted on laboratory animals scientists of the Ural state Academy of veterinary medicine, found that glauconite has no toxic effects and on the classification of chemicals by hazard in accordance with the state standard 12.1.007.76 belongs to the class 4 - slightly dangerous substances (Maltseva L. F., Sunagatullin F. A., Ovchinnikov A. A., Rasetti S. A. Irritating and allergenic action of glauconite Carian field // Mat. Dokl. All-Russian. Conf. devoting to research and development. the 20th anniversary of Urals. branch of VIEWSHE. - Moscow, Chelyabinsk. - 1999. - p. 115-116,. Sunagatullin F. A., Ovchinnikov A. A., Rasetti S. A., Maltseva L. F. Acute and chronic toxicity of glauconite // Mat. Dokl. All-Russian. Conf. devoting to research and development. the 20th anniversary of Uralsk. Branch of VIEWSHE. - Moscow, Chelyabinsk. - 1999, pp. 152-154).
Currently in medicine and veterinary medicine glauconite is used mainly as a component of various complex preparations used�both in human and veterinary medicine. Thus, it is proposed its use in the feed additive composition containing glauconite and probiotic "Biosporin" (EN 2319391, 2008) to increase protective forces and the natural resistance of the body of pigs.
A suspension of glauconite in an aqueous solution of agar is proposed for the treatment of calves, patients with dyspepsia (EN 2188652, 2002). For the prevention and treatment of diseases of the gastrointestinal tract offered the drug "toxi-Biovit" (EN 2475254, 2012) containing sterilized culture fluid of a number of microorganisms, 50,0-55,0% glauconite and excipients.
The disadvantage of these drugs is the instability during storage, caused a large proportion of glauconite, as well as lack of efficiency due to insufficient development of the surface of the earth.
The closest in technical essence to the claimed invention is enterosorbent (EN 2204396, 2003), consisting of glauconite concentrate that is used as the active substance for the prevention and treatment of diseases of the gastrointestinal tract. It can be applied both independently and as part of: medicinal products for the treatment of diseases of the digestive tract and feed for the prevention of gastrointestinal diseases in animals. Applies glauconitic concentrate in the form of powders, suspensions, emulsions, however, suspension glauconycteris due to the high density of the mineral.
Closest to the claimed method of obtaining enterosorbent is the technology on which glauconite is produced by grinding in the mill, the fraction collected with a particle size of 0.01 to 0.1 mm (EN 2188652, 2002), followed by cooking in a 0.5% aqueous solution of agar.
The disadvantages of enterosorbents on the basis of glauconite and the method of their production are the problem of their suspendirovanie in pure form and the instability of the resulting suspension due to its high density and lack of effectiveness of the final product.
The technical task of the invention is the creation of new enterosorbent on the basis of glauconite, which has a higher sorption capacity in the form of a stable aqueous suspension of glauconite that do not require special storage conditions (including freezing and thawing).
The technical result, in respect of the sorbent was achieved with the establishment of the enterosorbent, representing 40-80% suspension in water fraction from 1.0 to 10 μm of glauconite, activated ultrasonic cavitation effect.
Suspension with a concentration of glauconite less than 40% does not allow to use in the sorption capacity of the sorbent to the maximum extent suspension with a concentration of glauconite over 80% - storage stable. The use of more coarse-grained fracc�and reduces the stability of the suspension, the use of particles with size less than 0.1 μm is difficult for technological reasons.
The technical result concerning the method of obtaining enterosorbent consists in crushing the glauconite content of rocks from 20 to 95% in a ball mill with a sampling fraction of 0.001-0.01 mm, mixing it with water and treating the resulting mixture with ultrasound with a frequency of 15-25 kHz within 2-5 minutes.
The ultrasound frequency 15-25 kHz is chosen experimentally based on the technical capabilities of the author. Treatment less than 2 minutes reduces the specific surface of the enterosorbent, processing more than 5 minutes does not give significant effect.
The result is a stable suspension, characterized by high sorption properties due to the increased surface area of the granules of glauconite, convenience and efficacy in the form of a slurry and stored in a wide temperature range from minus 30 to plus 50°C.
The use of ultrasound for the dispersion due to the specific cavitation phenomena accompanying the propagation of ultrasonic oscillations in liquid media (ru.wikipedia.org/wiki/). Thus formed in the liquid gas bubbles (cavities) in which as consider, electrical discharges occur, the ionization of molecules and atoms, the pressure increase and the�of oratory. Gas (cavitation) bubbles are easier to form on the boundary of the liquid with the solid, acting vigorously on the surface of the last. In the process of ultrasonic treatment changes the surface of the suspended mineral, and the resulting finely divided products differ both in the composition and structure of the surface.
The presence of a layered structure of glauconite, unlike zeolites, which are characterized by a frame structure, leads to the fact that some intramolecular forces are not balanced by interaction with ions contained in the solution or air. As a result, they accumulate on the active surfaces of the platelets that make up the crystal, so that after the cavitation treatment significantly increased active surface area of the sorbent.
The nature and advantages of the method are illustrated by the following examples.
Example 1. Glauconite was pulverized in a ball mill to select size of 1-10 μm, and then subjected to magnetic separation at magnetic drum type separators SBM NPO "Erg" variable induction, from 200 to 250 MT and the field gradient from 50 to 70 MT/cm for the selection of the breed, containing from 20 to 95% of the content of glauconite.
Then in container filled with purified water and then filled prepared glauconite Ministers in�the sections on weight 70/30-40/60-50/50-80/20-85/15, and then the mixture is exposed to ultrasound of a frequency of 15-25 kHz, the delay time is 2-5 min. ultrasonic Power 3 W/cm2. The moisture content of the resulting slurry is in the range from 25 to 65%.
Sorption activity of the enterosorbent obtained, IONEX suspension (is), is defined as the specific surface, causing its activity. The specific surface of the sorbent during the sorption of nitrogen, calculated according to the BET method (method proposed by Brunauer, Emmett and Taylor), are shown in table 1.
|The influence of the production conditions on the properties of enterosorbent|
|The ratio of glauconite:water||Conditions of processing||The specific surface of the sorbent, m2/g||The duration of storage without delamination, d|
|Frequency||The duration of treatment, min|
Example 2. Determination of the adsorption activity conducted in relation to the methylene blue dye (marker of low molecular weight toxins) and to the dye Congo red. The results are shown in table 2:
|Adsorption activity of the enterosorbent (ratio of glauconite:water 50:50)|
|Product||Adsorption activity, mg/g||Serum albumin (NAV 0.5% aqueous solution) at an initial concentration of protein solution 1000 mg/l|
|methylene blue||Congo red|
|Activated charcoal||of 200.2±9,8||1,1±0,1||61,6±9,7|
From the experimental results it follows that IP on the adsorption activity is significantly superior to the sorption activity of commercially available analogues.
The suspension of dispersed natural glauconite, has high enterosorbiruyuschee ability, non-specific detoxification effect and probiotic activity. It binds and removes from the body of pathogenic bacteria and bacterial toxins, drugs, poisons, heavy metals, alcohol, allergens, and also the excess of certain metabolic products, including bilirubin, cholesterol, urea, metabolites, responsible for the development of endogenous toxemia. Unlike antibiotics leads to the development of dysbiosis. It is not toxic and is not absorbed completely eliminated from the intestine within 24 hours.
1. The method of obtaining enterosorbent on the basis of glauconite, which includes the grinding of glauconite, a selection of his faction, mixing with the liquid fazoli suspending the resulting mixture, characterized in that after grinding the glauconite content of rocks from 20 to 95% of the fraction collected from 1.0 to 10 microns, is prepared 40-80% suspension of glauconite in the water, and then the resulting mixture is treated with ultrasound with a frequency of 15-25 kHz within 2-5 minutes.
2. Enterosorbent on the basis of glauconite, obtained by the method according to claim 1, representing 40-80% suspension in water fraction from 1.0 to 10 μm of glauconite, activated ultrasonic cavitation effect.
SUBSTANCE: group of inventions refers to veterinary science. A method for preparing a herbal therapeutic preparation for treating gastrointestinal diseases in young animals is characterised by the fact that 150-200 g of ground elm bark is placed into a thermally stable flask filled with 500 ml of distilled water, extracted for 3 days in the cold environment; the flask is then placed on a gas or electric stove, connected through a laboratory fridge to a cold water source; distillation of a liquid fraction is followed by sublimation of a solid fraction for 6-8 hours until the particles are carbonised completely; the preparation is collected in a sterile laboratory flask, and then agitated. A method of using the therapeutic preparation produced as described above is characterised by the fact that the preparation is administered into young animals of various species in a dose of 3-25 ml intraperitoneally once a day; in some cases, the preparation is administered again 48-72 hours later. The invention provides the fast and effective action of the preparation ensured by chemical composition and applicability of the preparation by intraperitoneal route of administration; ensuring the fast effect of the pathological process specific for the gastrointestinal tract.
EFFECT: preparation provides anti-inflammatory action on the involved gastrointestinal mucous membranes, relieves the inflammatory process considerably, and thereby reduces the receptor irritation that leads to normalising intestinal peristalsis and reducing diarrhoea.
2 cl, 2 tbl
SUBSTANCE: first doctor's appointment involves evaluating pulp cavity injuries visually, and prescribing a therapeutic preparation in the form of a paste for inflammation relief. The paste-like therapeutic preparation is Metrogyl Denta gel with either laevomycetin, or metronidazole; the paste is prepared with ex tempore Metrogyl Denta gel with laevomycetin in the following proportions: Metrogyl Denta gel - 0.25-0.35 g; laevomycetin - 0.07-0.09 g (1/5-1/7 of laevomycetin tablet 0.5 g or 2/5-2/7 of laevomycetin tablet 0.25 g), or ex tempore Metrogyl Denta gel with metronidazole in the following proportions: Metrogyl Denta gel - 0.25-0.35 g; metronidazole - 0.05-0.036 g (1/5-1/7 of metronidazole tablet 0.25 g).
EFFECT: method enables reducing inflammation and reducing the number of complications.
4 dwg, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for preventing or treating gastrointestinal dysmotilities and to a food functional therapeutic composition for preventing or treating gastrointestinal dysmotilities; the above compositions contain mixture of two or more herbs specified in a group consisting of Bupleuri Radix, Coptidis Rhizoma and Glycyrrhizae Radix et Rhizoma.
EFFECT: compositions provide the synergetic effect on preventing or treating gastrointestinal disorders, particularly functional dyspepsia associated with a rate of gastric emptying or a gastrointestinal transit.
6 cl, 5 tbl, 13 ex
SUBSTANCE: polypeptide has a sequence represented by the formula below X1 Va1 X2 Ile Phe Thr Tyr Gly X3 Leu Gln Arg X4 Gln Glu Lys Glu Arg X5 Lys Pro Gln (formula I). Links between amino acids, apart from X1-Val link, are amide links. The X1-Val link is an amide link or a link represented by the formula below 2
X1 is an aromatic amino acid or a heteroaromatic amino acid, X2 represents proline or sarcosine, X3 is glutaminic acid or asparaginic acid, X4 is methionine or leucine, X5 is asparagine or proline. The proposed invention may be used in medicine for treatment of a disease related to disturbed function of gastrointestinal tract.
EFFECT: invention makes it possible to efficiently treat diseases related to disturbed function of gastrointestinal tract.
7 cl, 5 dwg, 4 tbl, 5 ex
SUBSTANCE: invention represents enterosorbent in form of pill, which contains colloidal silicon dioxide, microcrystal cellulose, dextrose, sodium croscarmellose, pharmaceutical talc and magnesium stearate, and components in enterosorbent are in specified ratio in wt %.
EFFECT: increase of sorption capacity and considerable reduction of production process due to reduction of granulate drying operation.
FIELD: veterinary medicine.
SUBSTANCE: agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome comprises wt % silver nitrate 0.01-0.5, levamisole base 3.0-8.0, ascorbic acid 1.0-12.0 and water for injection - the rest.
EFFECT: antibacterial, immunomodulatory effect, anti-stress, antioxidant effect, and increase in effectiveness of prevention of gastrointestinal diseases in calves with diarrhea syndrome.
10 tbl, 6 ex
SUBSTANCE: invention relates to medication, representing betulin bis-isonicotinoate .
EFFECT: low toxicity, expressed anti-ulcer, anti-inflammatory and hepatoprotective activity.
3 tbl, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a composition for treating anal fissures in the form of a hydrous gel, containing an active compound in the form of isosorbide dinitrate, a gelation agent, a neutralising agent and a solvent differing by the fact that the composition contains triethanolamine as the neutralising agent taken in equal proportions with the gelation agent which is presented by a lightly crosslinked polymer; the solvent is presented with a mixture of polyethyleneoxide and ethanol in ratio 5-6:1:3-4 with the ingredients of the composition taken in certain proportions, wt %.
EFFECT: invention provides higher clinical effectiveness and reduced length of treatment.
3 ex, 2 tbl
SUBSTANCE: what is used is botulinum toxin A in a dose of 20-35 Units administered into 4 points of 1, 5, 7 and 11 o'clock of the internal anal sphincter in a combination with subcutaneous administration of botulinum toxin 5-7 Units under the fissure from its distal end. Besides, a condition medium of mesenchymal stem cells in an amount of 20-30 ml is introduced into the rectum.
EFFECT: higher clinical effectiveness in the anal fissure and lower number of therapeutic injuries.
SUBSTANCE: haemorrhoidectomy involving removing haemorrhoids en bloc with an anal wound closure is followed by daily dressings from the first postoperative day with using the antibacterial preparation Levomecol. That is combined with a therapeutic parenteral administration of standard analgesics and taking sitting baths and conducting a local physiotherapy. The preoperative preparation involves prescribing the complex immunomodulator Kipferon presented in the form of suppositories containing 500000 IU of interferon alpha-2 and 60 mg of complex immunoglobulin preparation. The preparation is administered in a dose of one suppository twice a day for 5 days preceding the haemorrhoidectomy. Then, administering the preparation is continued once a day in the same dose from the second to the eleventh postoperative day. The preoperative preparation is also added with prescribing the phlebotonic diosmin (Venarus, Detralex) orally in a dose of 500 mg twice a day for 3 days preceding the haemorrhoidectomy and continued in the same dose twice a day from the first to eighth postoperative day. Besides, from the second postoperative day the osmotic laxative Lactulose is administered orally in a dose of 15-25 ml once until the patient has an unassisted defecation.
EFFECT: lower postoperative post-defecation pain syndrome as estimated by VAS analogue scale, less manifested perianal tissue oedema within the operative tissues, shorter wound epithelisation as shown by a cytological pattern of impression smears, achieved adequate elimination of the postoperative complications in the form of bleedings, reflex urinary retention, formation of deforming adhesions, reduced bacterial content of the anal wounds, shorter time of patient's anal sphincter hypertonus, as well as adequate time of postoperative defecation recovery.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a therapeutic agent used for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by a multifunction kinase inhibitor (MKI) therapy and containing a therapeutically effective amount of allopurinol or its pharmaceutically acceptable salt.
EFFECT: invention provides extending the range of products for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by the multifunction kinase inhibitor (MKI) therapy.
21 cl, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and represents a vaccine composition for inducing an immune response in animals. The composition contains an antigen and a 40% oil-in-water emulsion diluted to 2.5%, wherein the above 40% oil-in-water emulsion contains 30 vl/vl % of light hydrocarbon non-metabolic oil, 10 vl/vl % of lecithin, 0.6 vl/vl % of sorbitan monooleate, 1.4 vl/vl % of polyoxyethylene sorbitan monooleate; the oil component is dispersed in an aqueous component by emulsification, while the vaccine composition is prepared by a microfluidiser. An average drop size in the composition makes less than 0.3 mcm.
EFFECT: composition possesses improved physical characteristics, enhanced immunising action, as well as high safety.
10 cl, 20 ex, 17 tbl, 11 dwg
SUBSTANCE: as an active substance, the composition contains butoconazol, a base that is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and also a gel-forming polymer. Hydroxypropylstarch phosphate is preferentially used as the gel-forming polymer. A method for preparing the declared composition consists in the fact that a mixture of butoconazol with a portion of the hydrophilic ingredient, the hydrophobic ingredient and emulsifier is added with a dispersion of the gel-forming polymer in the rest of the hydrophilic ingredient; the produced mixture is agitated homogenously with a preserving agent added where it might be necessary.
EFFECT: new pharmaceutical composition is characterised by a high level of antifungal activity, stability both at a storage temperature, and at a use temperature, and good pack extrusion.
14 cl, 2 tbl, 10 ex
SUBSTANCE: claimed is application of fat emulsion for parenteral feeding as solvent for compounds which are poorly soluble in water. Fat emulsion contains in 1 l of solution: 30 g of refined soybean oil, 30 g of triglycerides with the average chain length, 25 g of olive refined oil, 15 g of purified fish oil.
EFFECT: obtaining solvent for compounds, poorly soluble in water, which makes it possible to determine parameters and spectrum of biological activity of novel compounds of chemical nature at the stages of pre-clinical and clinical tests, which does not change basic biological constants and possesses biological inertness.
2 tbl, 2 ex
SUBSTANCE: invention represents a producing method of cream containing fusidic acid, which involves a stage of application of sodium fusidate as an initial active ingredient and conversion of the above sodium fusidate in situ to fusidic acid in an oxygen-free medium by immediate addition of the acid to a cream base containing a preservative, an acid, a cosolvent, an emulsifier, a wax-like product and water.
EFFECT: obtaining cream having high stability at storage and smaller particles of an active ingredient.
9 cl, 11 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and represents dermatological cream, intended for local treatment of bacterial skin infections and for healing wounds associated with them, which contains framycetin sulfate and biopolymer, included into cream base, which contains at least one substance from each of the following groups: preservative, primary and secondary emulsifier, selected from the group which contains ketostearyl alcohol, ketomacrogol 1000, polysorbate-80 and Span-80; paraffin as wax-like product, cosolvent, selected from the group, including propylene glycol, hexylene glycol and polyethylene glycol-400; nitric acid or lactic acid and water, with said biopolymer preferably being chitosan.
EFFECT: invention provides higher therapeutic effect.
8 cl, 10 tbl, 2 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutics and represents a pharmaceutical composition for parenteral administration containing sub-micron particles of dosocahexaenoic acid ester dispersed in a water phase with the use of mixture of at least two surfactants specified in a) at least one fatty acid polyoxyethylene ester and b) at least one phospholipide derivative, as well as a method for preparing the above pharmaceutical composition.
EFFECT: invention provides higher pharmacological activity.
14 cl, 3 dwg, 3 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical and cosmetic industry, in particular to nanoemulsions of a water-in-oil type for transdermal application with biologically active compounds.A nanoemulsion of the water-in-oil type contains 35-80% of a hydrophobic phase, 1-15% of a hydrophilic phase, and a surface-active substance.
EFFECT: nanoemulsion of the water-in-oil type for transdermal application with biologically active compounds possesses good storage stability.
8 cl, 1 dwg, 1 tbl
SUBSTANCE: aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition.
EFFECT: invention provides low toxicity of dosage form and high efficiency.
5 cl, 3 tbl, 1 ex
SUBSTANCE: composition containing curcumine, an acid specified in a group consisting of citric acid, malic acid, acetic acid, tartaric acid, lactic acid, alginic acid or a mixture thereof, and an edible emulsifying agent with specific characteristics and taken in a certain amount wherein the above composition is applicable as a therapeutic agent. The composition containing curcumine, the edible emulsifying agent or a mixture thereof, the acid specified in a group consisting of citric acid, malic acid, acetic acid, tartaric acid, lactic acid, alginic acid or a mixture thereof taken in certain proportions, and additionally encapsulated into a gelatine capsule, wherein the above composition is applicable for treating or preventing an inflammation and/or diseases caused by the inflammation.
EFFECT: compositions improve the curcumine bioavailability effectively.
13 cl, 1 tbl, 6 ex
SUBSTANCE: method is characterised by the fact that 100 mg of iron sulphate or zinc sulphate are dissolved in 1 ml of water and obtained mixture is dispersed into carrageenan solution in acetone, which contains 300 mg of carrageenan, in presence of 0.01 g of E472c preparation with mixing. After that, 2 ml of ethanol are added, obtained suspension is filtered and dried at room temperature, with realisation of the method without special equipment.
EFFECT: simplification and acceleration of the process of obtaining microcapsules and increase of output by mass.